- Home
- STAI vs AYTU Comparison
STAI vs AYTU Comparison
Compare STAI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- AYTU
- Stock Information
- Founded
- STAI 2011
- AYTU N/A
- Country
- STAI United States
- AYTU United States
- Employees
- STAI N/A
- AYTU N/A
- Industry
- STAI
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- AYTU Health Care
- Exchange
- STAI Nasdaq
- AYTU Nasdaq
- Market Cap
- STAI 24.6M
- AYTU 23.0M
- IPO Year
- STAI N/A
- AYTU N/A
- Fundamental
- Price
- STAI $0.46
- AYTU $2.21
- Analyst Decision
- STAI
- AYTU Strong Buy
- Analyst Count
- STAI 0
- AYTU 3
- Target Price
- STAI N/A
- AYTU $9.17
- AVG Volume (30 Days)
- STAI 14.9M
- AYTU 148.2K
- Earning Date
- STAI 09-17-2025
- AYTU 11-13-2025
- Dividend Yield
- STAI N/A
- AYTU N/A
- EPS Growth
- STAI N/A
- AYTU N/A
- EPS
- STAI N/A
- AYTU N/A
- Revenue
- STAI $1,249,524.00
- AYTU $66,382,000.00
- Revenue This Year
- STAI N/A
- AYTU N/A
- Revenue Next Year
- STAI N/A
- AYTU $29.12
- P/E Ratio
- STAI N/A
- AYTU N/A
- Revenue Growth
- STAI 139.30
- AYTU 1.84
- 52 Week Low
- STAI $0.35
- AYTU $0.95
- 52 Week High
- STAI $9.07
- AYTU $2.82
- Technical
- Relative Strength Index (RSI)
- STAI 44.37
- AYTU 47.64
- Support Level
- STAI $0.48
- AYTU $2.23
- Resistance Level
- STAI $0.73
- AYTU $2.31
- Average True Range (ATR)
- STAI 0.07
- AYTU 0.13
- MACD
- STAI -0.01
- AYTU -0.01
- Stochastic Oscillator
- STAI 2.07
- AYTU 28.57
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.